Could a simple pill tame long COVID's immune chaos?
NCT ID NCT07189936
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a drug called 2-HOBA can reduce immune system overactivity in people with Long COVID who also have POTS (a condition causing rapid heart rate upon standing). The study will enroll 50 participants and randomly assign them to receive either 2-HOBA or a placebo for 28 days. Researchers will measure immune markers and symptoms to see if the drug helps calm the persistent immune response thought to drive many Long COVID symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
2-hydroxybenzylamine (2-HOBA)
What this could lead to
If it works, this could point toward a treatment that reduces immune system overactivity and improves symptoms like fatigue and rapid heart rate in Long COVID POTS patients.
What could go wrong
This is a small early-phase trial with only 50 participants, so results may not apply to everyone. The drug may not reduce immune markers or improve symptoms better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cyndya Shibao
RECRUITINGNashville, Tennessee, 37027, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••